Despite proven efficacy and tolerability in diverse heart failure populations, beta-blocker utilization remains low, highlighting the need for improved initiation and up-titration strategies.
Answers are grounded in this paper and cite their sources.
May support beta-blocker use in elderly, diabetic, and advanced HF; leaves open strategies to raise real-world adoption.
The beneficial effects of beta-blocker therapy in patients with heart failure have been consistently shown by multi-center randomised trials. These agents are effective and also relatively well tolerated in the elderly and in patients with diabetes and advanced heart failure--traditionally considered as relative contraindications to their administration. However, the use of beta-blockers in clinical practice remains low. The difficulties in their initiation and up-titration may be overcome by patient and physician education, as well as by their initiation during hospitalisation and/or the involvement of non-physician providers (i.e., a nurse facilitator). Forthcoming advances in the pharmacokinetic and pharmacodynamic characteristics of some beta-blockers, and testing of novel methods for patient and drug selection may be based on genetic testing, and may allow further improvement of beta-blocker therapy in the next future.
No takes yet. Share an insight, caveat, or question.
Metra et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: